Alternative injection site for goserelin in breast cancer patients
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial is testing whether giving the drug goserelin in a different spot on the body works just as well for suppressing ovarian function in premenopausal women with hormone receptor positive breast cancer. You may be a fit if you've already been on goserelin shots in your abdomen for at least 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 49 with hormone receptor positive breast cancer (stage I to III) and have finished your main treatment with no signs of cancer.
- You are currently getting monthly goserelin shots in your belly to stop your ovaries from working, along with either an aromatase inhibitor or tamoxifen, and plan to continue this for at least another year.
- You have been on goserelin for at least 6 months and have had blood tests showing your estradiol (a hormone) level is well suppressed.
- You are willing to have blood drawn for research and to fill out questionnaires.
- You are able to get pregnant and agree to use effective birth control during the study and for 3 months after.
- You have not had chemotherapy in the last 6 months and are not using any estrogen or progestin containing products.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two hormone-blocking injections (leuprolide and goserelin) to suppress ovarian function in premenopausal women with breast cancer. It aims to see how well these drugs work when taken with standard hormone pills.
This trial tests whether combining immunotherapy, hormone therapy, and an AKT-blocking drug can control ER-positive advanced breast cancer in women whose cancer is resistant to hormone treatment. It may help shrink tumors and slow disease by targeting several pathways at once.
This study tests whether switching the type of ovarian-suppressing medication helps keep hormone-sensitive breast cancer under control in younger women. You'll be screened to see if your current treatment is working, then potentially switched to a different formulation to see if it works better.
This trial tests whether adding a hormone-blocking drug (GnRH agonist) to standard chemotherapy before surgery helps premenopausal women with triple-negative breast cancer. It aims to improve treatment outcomes by targeting hormones that may fuel tumor growth.
This Phase 3 trial compares hormone-based treatment versus chemotherapy given before surgery in people who are premenopausal and have hormone-receptor positive, HER2-negative breast cancer. It looks to see which approach works better to control the cancer before the breast operation.
This Phase 2 study tests whether using hormone (endocrine) treatment alone can control breast cancer in people age 70 and older. It targets breast cancers that are estrogen-receptor positive and HER2 negative, aiming to avoid chemotherapy-like treatments in suitable patients.
Hear when a new Anatomic Stage I Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.